Unknown

Dataset Information

0

Decreased susceptibility of Neisseria gonorrhoeae isolates from Switzerland to Cefixime and Ceftriaxone: antimicrobial susceptibility data from 1990 and 2000 to 2012.


ABSTRACT: BACKGROUND: Neisseria gonorrhoeae can rapidly develop resistance to antimicrobial agents. Over the last years, decreased gonococcal susceptibility to third-generation cephalosporins, especially cefixime, emerged worldwide. Therefore, current international guidelines recommend dual therapy for gonorrhoea with ceftriaxone plus either azithromycin or doxycycline. Gonococcal susceptibility data in Switzerland are sparse. METHODS: We investigated the prevalence of antibiotic susceptibility of N. gonorrhoeae in specimens collected between 1990 and 2012 at the University of Zurich, Switzerland. Minimum inhibitory concentrations (MICs) for cefixime, ceftriaxone, ciprofloxacin, and penicillin were determined by Etests. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints were used to define reduced susceptibility. RESULTS: A total of 320 isolates were tested. Between 1990 and 2006 all tested samples were susceptible to both cephalosporins. Subsequently, the prevalence of elevated MICs for cefixime increased to 10.4% (2007/2008), 11.5% (2009/2010), and 11.4% (2011/2012); and for ceftriaxone to 2.4% (2007/2008), 4.7% (2009/2010), and 0% (2011/2012), respectively. The prevalence of resistance to ciprofloxacin (72.7%) and penicillin (22.7%) was high in 2011/2012. CONCLUSIONS: Decreasing susceptibility of N. gonorrhoeae to third-generation cephalosporins in Switzerland supports treatment recommendations with ceftriaxone plus azithromycin or doxycycline. Health-care providers need to be aware of possible treatment failures with cephalosporins. Continued surveillance of gonococcal antimicrobial resistance is essential.

SUBMITTER: Kovari H 

PROVIDER: S-EPMC3881505 | biostudies-other | 2013

REPOSITORIES: biostudies-other

altmetric image

Publications

Decreased susceptibility of Neisseria gonorrhoeae isolates from Switzerland to Cefixime and Ceftriaxone: antimicrobial susceptibility data from 1990 and 2000 to 2012.

Kovari Helen H   de Melo Oliveira Maria Dg MD   Hauser Paula P   Läuchli Severin S   Meyer Jürg J   Weber Rainer R   Zbinden Reinhard R  

BMC infectious diseases 20131226


<h4>Background</h4>Neisseria gonorrhoeae can rapidly develop resistance to antimicrobial agents. Over the last years, decreased gonococcal susceptibility to third-generation cephalosporins, especially cefixime, emerged worldwide. Therefore, current international guidelines recommend dual therapy for gonorrhoea with ceftriaxone plus either azithromycin or doxycycline. Gonococcal susceptibility data in Switzerland are sparse.<h4>Methods</h4>We investigated the prevalence of antibiotic susceptibili  ...[more]

Similar Datasets

| S-EPMC5403062 | biostudies-literature
| S-EPMC4696695 | biostudies-literature
| S-EPMC8030720 | biostudies-literature
| S-EPMC4263019 | biostudies-literature
| S-EPMC5782888 | biostudies-literature
| S-EPMC3941690 | biostudies-literature
| S-EPMC6932624 | biostudies-literature
| S-EPMC2837549 | biostudies-literature
| S-EPMC3294943 | biostudies-literature
| S-EPMC6350947 | biostudies-literature